[Local therapeutic trials of various forms of extrapulmonary tuberculosis using rifampicin suspension].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A Basacopol.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Two hundred patients with various chronic pulmonary diseases were treated with the bacterial lysate Broncho-Vaxom (BV) in addition to conventional treatment, or alone, over a period of 2 years. The efficacy of BV was assessed ob the basis of clinical symptoms (dyspnoea, cough, expectoration, fever and bronchial rales), pulmonary function, number of relapses and immune status, in particular serum immunoglobulins A, G and M. The results demonstrated the efficacy of BV in the treatment and prevention of chronic pulmonary disease. In patients treated with BV, clinical symptoms improved significantly compared to controls, incidence of infectious episodes was reduced and impaired immune functions were restored. BV was generally well tolerated.
Explore the source record for details and available documents.
206 sera collected from different groups of subjects were analyzed by immunoenzymatic methods regarding the content of Mycobacterium tuberculosis specific antibodies and mycobacterial antigens. The results underlined that two assays offered improved serologic diagnosis of tuberculosis over a single antibody test. BCG vaccination interferes with serologic tests for tuberculosis when polyspecific antibodies or mixture of common and specific antigens are used as immunologic reagents. A mycobacterial antigens circadian variation in correlation with vesperal fever in tuberculous patients was not revealed. The mycobacterial antigens seem to become undetectable, in sera, after 6 months of efficient treatment.
"Two-assay" tests (TAT), immunoenzymatic determination of both specific antibodies and mycobacterial antigens in sera of tuberculous and non-tuberculous subjects, was undertaken in our territorial conditions, where BCG vaccination is systematically applied and the prevalence of tuberculous infection is relatively high. The sensitivity of the method, calculated on 42 patients with active pulmonary tuberculosis and on 39 patients with post-tuberculosis syndromes is high, i.e. 0.952. The specificity of the method separately calculated for 44 young subjects (under 21 years old), for 78 healthy adults and for 201 lung diseased patients, bacteriologically not ascertained as tuberculosis at the moment of sera prelevation, varied between 0.830 and 0.489. "TAT", performed with crude immunologic reagents, produces false-positive reactions in early BCG vaccinated subjects. Method specificity low values in pulmonary non-tuberculous patients group may be partially explained by the difficulty in establishing the real relationships, in time, between host and mycobacteria, by the bacteriological method imperfections or sample prelevating methods. Our results certainly underestimate the diagnosis value of "TAT".
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Corticoid therapy with dosed aerosols is one of the achievements that have been made lately in the treatment of bronchial asthma. In view of establishing the efficiency of this type of treatment two preparations have been used: Auxiloson (isonicotinate of dexamethasone), and Becotide (dipropionate of belcomethasone), in two groups of patients. The favourable results obtained involved over 80% of the patients treated with each of these drugs. The use of corticoid therapy with dosed aerosols in the treatment of bronchial asthma reduces many of the risks of the general therapy with corticoids, and is indicated in the maintenance therapy of patients, between asthma attacks, in the intervals when the risk of such attacks is increased, and especially in the long term treatment of corticoid-dependent bronchial asthma.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.